Search company, investor...
Beacon Biomedical company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Grant - II | Alive

Total Raised


Last Raised

$30K | 7 mos ago

About Beacon Biomedical

Beacon Biomedical is a medical diagnostic development and a Centers of Medicare and Medicaid Services (CMS) CLIA accredited laboratory services company providing easy, accurate, and affordable blood tests for earlier cancer detection. Its laboratory-developed test (LDT) solutions are developed for healthcare practitioners and individuals alike and are intended to be used as screening tests for the presence of undiagnosed cancer. They are specifically designed for those who are unwilling or unable to participate in cancer screening using current procedures and tests. The company's focus is on providing blood-based cancer screening alternatives in order to improve screening participation and earlier detection of these devastating diseases. The company was founded in 2014 and is based in Pheonix, Arizona.

Beacon Biomedical Headquarters Location

275 N. GateWay Drive Suite 149

Phoenix, Arizona, 85034,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Beacon Biomedical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Beacon Biomedical is included in 5 Expert Collections, including Cancer.



3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'


Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,412 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Health IT

7,901 items

Beacon Biomedical Patents

Beacon Biomedical has filed 12 patents.

The 3 most popular patent topics include:

  • Orthopedic surgical procedures
  • Skeletal system
  • Bone fractures
patents chart

Application Date

Grant Date


Related Topics




Bones of the vertebral column, Orthopedic surgical procedures, Neurosurgery, Skeletal system, Surgical removal procedures


Application Date


Grant Date



Related Topics

Bones of the vertebral column, Orthopedic surgical procedures, Neurosurgery, Skeletal system, Surgical removal procedures



Latest Beacon Biomedical News

Arizona Business Leaders Reach Out In Support of SBIR/STTR Reauthorization

Jul 23, 2022

Posted on Forty-eight Arizona business leaders signed on to a letter delivered on July 22, 2022 to Arizona’s Congressional Delegation emphasizing the importance of reauthorizing the SBIR/STTR program. The letter, was signed by business leaders from: Arizona Bioindustry Association, Inc. (AZBio), Arizona Chamber of Commerce & Industry, Arizona Commerce Authority, Arizona Technology Council, Desert Angels, Inc., Greater Phoenix Chamber, Greater Phoenix Economic Council, Greater Phoenix Leadership, PHX East Valley Partnership, Southern Arizona Leadership Council (SALC), Tucson Metro Chamber, UAVenture Capital, University of Arizona, AdviNow Medical, Aesthetics Biomedical, Inc., Aqualung Therapeutics, Anuncia Medical, Inc., Beacon Biomedical, Becton Dickinson (BD), Biosensing Instrument, Inc., bioSyntagma, Inc., Calviri, Inc., Dignity Health, EthiX Associates, Exact Sciences, GT Medical Technologies, Inc., HonorHealth Research & Innovation Institute, Humabiologics, Inc., Langham Logistics, Inc., Mayo Clinic, Metfora, Microvascular Therapeutics, Navi Nurses, NuvOx Pharma, nVector, Plaza Companies, Regenesis Biomedical, Inc., Regional Center for Border Health, Inc.,  ReSuture Inc., SARRC, Scintillation Nanotechnologies, Inc., Sequitur Health Corp., SpencerFane, Translational Sciences, Inc.,  VMAS Solutions, Inc. (dba TouchPoint Solution), and Yelton and Associates. Since its inception in 1982, the SBIR/STTR program has supported our small business community as we work to improve health, develop new agricultural techniques, innovate for our national defense, explore space, and more. Across the agencies that participate in this essential program, Arizona small businesses have received 3,488 awards and over $1 billion in funding for research programs intended to meet the needs of these agencies, our country, and our people. Since the last SBIR/STTR reauthorization in 2016, 190 Arizona Small Businesses have received 623 awards totaling just under $268 million. The Small Business Innovation Research (SBIR) 3.2% set aside and the Small Business Technology Transfer (STTR) 0.45% set aside makes it possible for small, entrepreneurial firms to contribute their innovation talents to address defined needs of these agencies. SBIR/STTR ensures that small business has the opportunity to be part our country’s research and development enterprise. Based on review of the Arizona specific dataset of SBIR/STTR awards for the period from 2017 to 2021, our small business community’s highest award concentrations are with the Department of Defense (50%), NASA (16%), Department of Energy (10%), Health & Human Services (8%), and the National Science Foundation (7%). While many of these R&D programs are components that support larger agency program requirements, Arizonans’ work on NIH/HHS related programs illustrate projects that are designed to directly impact some of our greatest health challenges. Some examples of these developing health innovations include: Avery Therapeutics, a University of Arizona spin out company, is developing and engineered cardiac tissue for treating damaged or diseased hearts. Aqualung Therapeutics has begun human clinical trials in an effort to save lives for those afflicted with Acute Respiratory Distress Syndrome (ARDS). Biomotum is developing of a robotic ankle assist device to improve mobility in individuals with movement disorders Calviri, an Arizona State University spin out company, is developing a blood test for the early detection of cancers. CND Life Sciences has developed an accurate, evidence-based tool to help confirm a diagnosis of neurodegenerative disorders. Metfora is working to commercialize a blood test for diagnosing lung diseases based on the analysis of metabolites. Regulonix, a University of Arizona spin out company, is developing better therapeutics to treat chronic pain. SBIR/SSTR funding for health innovation is rarely sufficient to sustain the full development process let alone commercialization, but it can move the discovery process forward and begin the development process. The remaining stages require private sector partnerships and investments that are much greater than at the early R&D stage. Without SBIR/STTR funding, many potential health innovations won’t make it to commercialization. Innovative Arizona small businesses depend on the SBIR/STTR programs to address the research needs of our federal agencies. As they move their innovations forward, they grow their businesses, create jobs, and contribute to Arizona’s economy. A Defense Department assessment showed the SBIR/STTR Program has generated a 22:1 return for every federal dollar spent, and a study by the National Academy of Sciences found a commercialization rate of between 50-60% for SBIR/STTR investments-a win-win for the U.S. economy and taxpayer. Allowing even a short disruption of these programs could have negative consequences for high-tech small businesses that thrive on stability and predictability to budget and plan for the future – especially as we all work together to emerge from the COVID-19 pandemic and overcome the economic challenges it triggered.

Beacon Biomedical Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Beacon Biomedical Rank

  • When was Beacon Biomedical founded?

    Beacon Biomedical was founded in 2014.

  • Where is Beacon Biomedical's headquarters?

    Beacon Biomedical's headquarters is located at 275 N. GateWay Drive, Phoenix.

  • What is Beacon Biomedical's latest funding round?

    Beacon Biomedical's latest funding round is Grant - II.

  • How much did Beacon Biomedical raise?

    Beacon Biomedical raised a total of $1.53M.

  • Who are the investors of Beacon Biomedical?

    Investors of Beacon Biomedical include Flinn Bioscience Entrepreneurship Program, Desert Angels, Hyalescent Ventures and U.S. Department of Health and Human Services.

  • Who are Beacon Biomedical's competitors?

    Competitors of Beacon Biomedical include GRAIL and 3 more.

You May Also Like

Molecular You

Molecular You analyzes a range of biomarkers to show health risks and what the user can do about it. Its preventive health assessment analyze not only genetics, but also metabolites, proteins, nutrients, and toxins to give the user the full picture. Then, it designs a personal diet and fitness plan to help the user stay healthy.

Freenome Logo

Freenome is an AI genomics biotechnology company in South San Francisco, California. By using a blood test, Freenome can help detect and treat cancer quickly and efficiently.

Liquid Genomics

Liquid Genomics monitors patient therapy via blood-based molecular testing. Blood based testing is used to detect and quantify cancer gene mutations with high sensitivity using Digital PCR and or Allele Specific Blocker PCR for blood or tissue.

Blueberry Diagnostics Logo
Blueberry Diagnostics

Blueberry Diagnostics is a biotechnology company. It offers AI testing solutions to healthcare professionals to detect cancer in its early stages. The company was founded in 2019 and is based in Wilmington, Delaware.


GENECAST develops cancer screening kits that can diagnose and monitor cancer through liquid biopsy using its ADPS (Allele-Discriminating Priming System) technology.

20/20 GeneSystems Logo
20/20 GeneSystems

20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.